Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Berglind

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|December 19, 2019
Trial of Anifrolumab in Active Systemic Lupus ErythematosusEric F Morand, Richard Furie, Yoshiya Tanaka, et al.
The Lancet. Rheumatology|January 17, 2024
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard A Furie, Eric F Morand, Ian N Bruce, et al.
The Lancet. Child & Adolescent Health|January 12, 2023
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trialsEric A F Simões, Shabir A Madhi, William J Muller, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|December 19, 2019
Trial of Anifrolumab in Active Systemic Lupus ErythematosusEric F Morand, Richard Furie, Yoshiya Tanaka, et al.
The Lancet. Rheumatology|January 17, 2024
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard A Furie, Eric F Morand, Ian N Bruce, et al.
The Lancet. Child & Adolescent Health|January 12, 2023
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trialsEric A F Simões, Shabir A Madhi, William J Muller, et al.
Pageof 2